NICE recommends sparsentan for IgA nephropathy
27th May 2025 Uncategorised 0
First non-immunosuppressive dual-action therapy approved for eligible patients

More: NICE recommends sparsentan for IgA nephropathy
Source: News
First non-immunosuppressive dual-action therapy approved for eligible patients

More: NICE recommends sparsentan for IgA nephropathy
Source: News
© 1994 - 2026 B.M. Pharmaceuticals